Table 3.

Grade ≥3 TEAEs reported in ≥5% of patients with B-NHL who received loncastuximab tesirine (safety analysis set)

TEAEn (%)
≤90 µg/kg (n = 17)120 µg/kg (n = 42)150 µg/kg (n = 88)200 µg/kg (n = 36)Total (N = 183)
Any 9 (52.9) 32 (76.2) 69 (78.4) 31 (86.1) 141 (77.0) 
Neutrophil count decreased* 6 (35.3%) 12 (29.3) 35 (40.7) 18 (51.4) 71 (39.7) 
Platelet count decreased* 1 (5.9%) 7 (17.1) 25 (28.7) 15 (42.9) 48 (26.7) 
GGT increased 4 (23.5) 9 (21.4) 15 (17.0) 11 (30.6) 39 (21.3) 
Anemia 3 (17.6) 4 (9.5) 16 (18.2) 5 (13.9) 28 (15.3) 
Blood ALP increased 4 (23.5) 3 (7.1) 3 (3.4) 2 (5.6) 12 (6.6) 
Lymphocyte count decreased 4 (9.5) 6 (6.8) 2 (5.6) 12 (6.6) 
PD 2 (4.8) 9 (10.2) 11 (6.0) 
Febrile neutropenia 1 (5.9) 2 (4.8) 6 (6.8) 1 (2.8) 10 (5.5) 
Hypokalemia 8 (9.1) 2 (5.6) 10 (5.5) 
TEAEn (%)
≤90 µg/kg (n = 17)120 µg/kg (n = 42)150 µg/kg (n = 88)200 µg/kg (n = 36)Total (N = 183)
Any 9 (52.9) 32 (76.2) 69 (78.4) 31 (86.1) 141 (77.0) 
Neutrophil count decreased* 6 (35.3%) 12 (29.3) 35 (40.7) 18 (51.4) 71 (39.7) 
Platelet count decreased* 1 (5.9%) 7 (17.1) 25 (28.7) 15 (42.9) 48 (26.7) 
GGT increased 4 (23.5) 9 (21.4) 15 (17.0) 11 (30.6) 39 (21.3) 
Anemia 3 (17.6) 4 (9.5) 16 (18.2) 5 (13.9) 28 (15.3) 
Blood ALP increased 4 (23.5) 3 (7.1) 3 (3.4) 2 (5.6) 12 (6.6) 
Lymphocyte count decreased 4 (9.5) 6 (6.8) 2 (5.6) 12 (6.6) 
PD 2 (4.8) 9 (10.2) 11 (6.0) 
Febrile neutropenia 1 (5.9) 2 (4.8) 6 (6.8) 1 (2.8) 10 (5.5) 
Hypokalemia 8 (9.1) 2 (5.6) 10 (5.5) 

ALP, alkaline phosphatase.

*

Platelet count decreased and neutrophil count decreased are based on laboratory abnormality reporting; data for 4 patients (1 at 120 µg/kg, 2 at 150 µg/kg, and 1 at 200 µg/kg) were missing for neutrophil count decreased, and data for 3 patients (1 each at 120, 150, and 200 µg/kg) were missing for platelet count decreased.

Close Modal

or Create an Account

Close Modal
Close Modal